Shelley Force Aldred

Shelley Force Aldred has a diverse work experience in the biotechnology industry. Shelley is currently the CEO and Co-founder of Rondo Therapeutics since December 2019. Prior to that, they worked as a Consulting Senior Director - Antibody Discovery at Loxo Oncology at Lilly starting from June 2020. Shelley also served as an Executive Member in the Women's Leadership Program at Hipower starting in March 2018. Shelley has board memberships at Westcal Management from September 2016, and Excellergy from January 2021 to December 2021.

Shelley has held various leadership roles in different organizations, including VP Preclinical Development at Teneobio, Inc. from July 2015 to March 2019, Director of R&D at Active Motif from March 2013 to July 2015, and Co-Founder and COO at SwitchGear Genomics from June 2006 to March 2013. Shelley also worked as a Scientific Director for the Stanford ENCODE Project at Stanford University School of Medicine from February 2005 to June 2006.

Shelley Force Aldred holds a Ph.D. in Genetics from Stanford University School of Medicine and a B.S. in Genetics from the University of California, Davis. The specific start and end years for each degree are not provided.